SGMO - Sangamo Therapeutics, Inc.
| Previous Close | 11.05 |
| Open | 11.13 |
| Bid | 10.95 x 3200 |
| Ask | 11.84 x 1100 |
| Day's Range | 11.11 - 11.36 |
| 52 Week Range | 6.26 - 19.25 |
| Volume | 1,296,863 |
| Avg. Volume | 1,759,625 |
| Market Cap | 1.313B |
| Beta (3Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | Nov 6, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.50 |
- Simply Wall St.
Does Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Salary Reflect Performance?
Sandy Macrae has been the CEO of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) since 2016. This analysis aims first to...
- Thomson Reuters StreetEvents
Edited Transcript of SGMO earnings conference call or presentation 7-Aug-19 9:00pm GMT
Q2 2019 Sangamo Therapeutics Inc Earnings Call
Motley FoolSangamo Biosciences Inc (SGMO) Q2 2019 Earnings Call Transcript
SGMO earnings call for the period ending June 30, 2019.
- Motley Fool
What You'll Want to Know About Sangamo Therapeutics' Q2 Results
Pipeline progress was the big story in Q2 for this clinical-stage biotech.
- Zacks
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of 25.71% and -9.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Sangamo Therapeutics Reports Second Quarter 2019 Financial Results
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time
- Business Wire
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today that CEO Sandy Macrae will present at the 2019 Wedbush PacGrow Healthcare Conference in New York City. The Wedbush presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Earlier in the week, Dr. Macrae will participate in the BTIG Biotechnology Conference 2019 in a panel discussion, “Exploring the Novel Approaches to Treating Sickle Cell Disease”.
- Zacks
BioMarin (BMRN) Shares Down on Q1 Earnings & Sales Miss
BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.
- Business Wire
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today the appointment of Gary H. Loeb as Executive Vice President and General Counsel, effective immediately. Mr. Loeb will oversee all legal matters for Sangamo and will report to the Chief Executive Officer. “Gary brings dynamic experience in pharmaceutical compliance, legal operations, and executive leadership,” said Sandy Macrae, Sangamo's Chief Executive Officer.
- Business Wire
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today that the Company will release its second quarter 2019 financial results after the market closes on Wednesday, August 7, 2019. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.
- Business Wire
Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today the publication in Nature Biotechnology of a manuscript by Jeffrey Miller, Ph.D., and colleagues at Sangamo, describing two new strategies for optimizing the specificity of genome editing using zinc finger nucleases (ZFNs). The ability to engineer highly specific gene editing nucleases with little or no detectable activity at unintended genomic sequences is a key safety factor for therapeutic applications. The strategies entail engineering the two key functional regions within the ZFN structure, namely adjusting the binding affinity of the zinc finger array which recognizes DNA, and slowing the catalytic rate of the Fok1 cleavage domain.
- Motley Fool
Shake-Up in Big Weed
One of the marijuana industry’s pioneers was just ousted from Canopy Growth. What comes next?
- Motley Fool
Here's Why Sangamo Therapeutics Jumped 23% in June
The biotech's gene therapy to treat hemophilia A looks promising.
- Zacks
Sangamo Up As Gene Therapy Shows Promise in Hemophilia Study (Revised)
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
- Market Realist
Sangamo Therapeutics Rises on Positive Clinical Trial Results
On Friday last week, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced promising updated results from the Phase 1/2 ALTA trial.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Soliton, Inc. (NASDAQ: SOLY ) shares were ...
- Zacks
BioMarin (BMRN) to File for Hemophilia A Candidate in Q4
BioMarin (BMRN) plans to file regulatory applications for gene therapy candidate for severe hemophilia A in the fourth quarter of 2019.
- Motley Fool
What Happened in the Stock Market Today
Sangamo Therapeutics reported positive data on its gene therapy for hemophilia, and CannTrust Holdings received a noncompliance report from Canadian authorities.
- Investor's Business Daily
Gene Therapy Battle: Why Sangamo Therapeutics Is Thrashing Its Rivals
Sangamo stock popped Monday after the biotech company unveiled promising results for its Pfizer-partnered gene therapy in hemophilia A treatment. Sangamo stock jumped as much as 16.9%.
- InvestorPlace
Sangamo Therapeutics News: SGMO Stock Surges on Gene Therapy Study
Sangamo Therapeutics (NASDAQ:SGMO) stock was on the up and up to kick off the week as the business revealed that it has made some key forward progress in its gene therapy that is designed to treat hemophilia A.Source: Shutterstock The Richmond, Calif.-based business revealed on Friday -- along with its partner Pfizer (NYSE:PFE) -- updated data from its Phase I/II Alta study of SB-525, designed to treat the aforementioned blood ailment. The data was presented in Melbourne, Australia, which hosts the International Society on Thrombosis and Haemostasis congress.Sangamo and Pfizer highlighted data that showed, out of the four patients who were given the highest dose of 30 trillion vectors per kilogram, two of them rapidly experienced positive results. They attained normal and sustained levels of Factor VIII with no reported bleeding events or need to receive treatment with the factor for as long as 24 weeks.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe other two experienced Factor VIII activity kinetics that was consistent with the first two patients. Sangamo had presented interim data on eight patients that the biotechnology company treated with SB-525 in April, which indicated that the therapy was well-tolerated-the data also showed a dose-dependent increase in Factor VIII levels across the dosage cohorts.The California business was founded in 1995 and it focuses its treatments on helping patients with hemophilia and other genetic illnesses.SGMO stock is up about 3.5% on Monday following the news. More From InvestorPlace * 7 A-Rated Stocks to Buy for the Rest of 2019 * The 7 Top Small-Cap Stocks Of 2019 * 7 F-Rated Stocks to Sell for Summer * 7 Retail Stocks to Buy That Are Down in 2019 The post Sangamo Therapeutics News: SGMO Stock Surges on Gene Therapy Study appeared first on InvestorPlace.
- Motley Fool
Here's Why Sangamo Therapeutics Is Surging Today
Results released late on Friday gave investors a reason to cheer.
- TheStreet.com
Sangamo Shares Soar as Hemophilia Drug Shows Promise
Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.
- Business Wire
Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels
BRISBANE, Calif. & NEW YORK-- -- The first two patients treated at the 3e13 vg/kg dose level rapidly achieved normal, sustained Factor VIII levels with no reported bleeding events and no factor usage for as long as 24 weeks of follow-up The two patients more recently treated at the 3e13 vg/kg dose level demonstrated FVIII activity kinetics that appear consistent with the first two patients in this ...
- Benzinga
The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...
